Home/Monte Rosa Therapeutics/Philip Vickers, Ph.D.
PV

Philip Vickers, Ph.D.

Head of Research & Development

Monte Rosa Therapeutics

Monte Rosa Therapeutics Pipeline

DrugIndicationPhase
MRT-2359MYC-driven solid tumors and lymphomasPhase 1/2
MRT-6160Inflammatory and autoimmune diseasesPreclinical
CDK2 DegraderOncologyPreclinical